Form 4: Amylyx Pharmaceuticals Co-CEO Sells Shares to Cover Tax Obligations

Amylyx Pharmaceuticals Co-Chief Executive Officer, Joshua B. Cohen, sold 7,471 shares to cover tax obligations related to vesting restricted stock units.

Summary

• Joshua B. Cohen, Co-Chief Executive Officer of Amylyx Pharmaceuticals, sold 7,471 shares of common stock on January 6, 2025.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• The shares were sold at a weighted average price of $4.0466, with individual transaction prices ranging from $3.99 to $4.09.
• Following the transaction, Cohen directly owns 3,213,098 shares of Amylyx Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, with no indication of positive or negative sentiment.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations are a common practice across the industry.
• The sale of 7,471 shares is a relatively small transaction compared to the total shares owned by the executive, which is 3,213,098 shares.
• Similar transactions are regularly reported by executives at other publicly traded pharmaceutical companies.

Stakeholder Impact

• The sale of shares by the CEO is unlikely to have a significant impact on shareholders, employees, customers, suppliers, or creditors.

Key Dates

Keywords

Amylyx Pharmaceuticals, AMLX, Joshua B. Cohen, stock sale, insider trading, restricted stock units, tax obligations